Market Closed -
Bombay S.E.
11:00:48 09/05/2024 BST
|
5-day change
|
1st Jan Change
|
555.4
INR
|
-0.72%
|
|
-5.60%
|
+36.51%
|
Fiscal Period: März |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
20,123
|
13,697
|
10,656
|
21,776
|
18,330
|
20,351
|
Enterprise Value (EV)
1 |
6,011
|
5,715
|
6,268
|
19,829
|
18,094
|
21,638
|
P/E ratio
|
1.02
x
|
-57.5
x
|
-17.7
x
|
63.4
x
|
55.6
x
|
-10.1
x
|
Yield
|
1.75%
|
2.06%
|
2.64%
|
1.29%
|
1.54%
|
-
|
Capitalization / Revenue
|
2.46
x
|
1.16
x
|
0.88
x
|
1.76
x
|
1.44
x
|
1.52
x
|
EV / Revenue
|
0.73
x
|
0.48
x
|
0.52
x
|
1.61
x
|
1.42
x
|
1.61
x
|
EV / EBITDA
|
-4.56
x
|
-8.32
x
|
-11.4
x
|
23.6
x
|
24.2
x
|
-45.1
x
|
EV / FCF
|
-2.4
x
|
-1.17
x
|
-2
x
|
-9.72
x
|
-5.18
x
|
-29.2
x
|
FCF Yield
|
-41.6%
|
-85.6%
|
-49.9%
|
-10.3%
|
-19.3%
|
-3.42%
|
Price to Book
|
0.75
x
|
0.52
x
|
0.42
x
|
0.85
x
|
0.7
x
|
0.84
x
|
Nbr of stocks (in thousands)
|
70,337
|
70,383
|
70,406
|
70,406
|
70,406
|
70,406
|
Reference price
2 |
286.1
|
194.6
|
151.4
|
309.3
|
260.4
|
289.0
|
Announcement Date
|
03/07/18
|
29/06/19
|
04/08/20
|
02/07/21
|
12/07/22
|
30/08/23
|
Fiscal Period: März |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
8,180
|
11,800
|
12,106
|
12,351
|
12,698
|
13,430
|
EBITDA
1 |
-1,317
|
-687.3
|
-551.6
|
838.6
|
747
|
-480.2
|
EBIT
1 |
-1,823
|
-1,362
|
-1,298
|
72.76
|
-109
|
-1,556
|
Operating Margin
|
-22.28%
|
-11.54%
|
-10.72%
|
0.59%
|
-0.86%
|
-11.58%
|
Earnings before Tax (EBT)
1 |
-1,298
|
-599.1
|
-482.1
|
514.8
|
219.7
|
-1,764
|
Net income
1 |
25,449
|
-238
|
-601.8
|
343.2
|
330.6
|
-2,022
|
Net margin
|
311.11%
|
-2.02%
|
-4.97%
|
2.78%
|
2.6%
|
-15.06%
|
EPS
2 |
280.6
|
-3.383
|
-8.550
|
4.875
|
4.680
|
-28.72
|
Free Cash Flow
1 |
-2,501
|
-4,889
|
-3,131
|
-2,041
|
-3,495
|
-740.5
|
FCF margin
|
-30.57%
|
-41.43%
|
-25.86%
|
-16.52%
|
-27.52%
|
-5.51%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
5.000
|
4.000
|
4.000
|
4.000
|
4.000
|
-
|
Announcement Date
|
03/07/18
|
29/06/19
|
04/08/20
|
02/07/21
|
12/07/22
|
30/08/23
|
Fiscal Period: März |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
1,288
|
Net Cash position
1 |
14,112
|
7,981
|
4,388
|
1,948
|
236
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-2.681
x
|
Free Cash Flow
1 |
-2,501
|
-4,889
|
-3,131
|
-2,041
|
-3,495
|
-740
|
ROE (net income / shareholders' equity)
|
-7.11%
|
-0.96%
|
-2.34%
|
1.35%
|
1.28%
|
-8%
|
ROA (Net income/ Total Assets)
|
-4.83%
|
-2.68%
|
-2.58%
|
0.15%
|
-0.21%
|
-2.99%
|
Assets
1 |
-526,722
|
8,870
|
23,346
|
236,723
|
-156,394
|
67,714
|
Book Value Per Share
2 |
381.0
|
372.0
|
360.0
|
363.0
|
372.0
|
346.0
|
Cash Flow per Share
2 |
94.70
|
28.00
|
32.10
|
11.00
|
15.50
|
26.10
|
Capex
1 |
1,596
|
1,943
|
3,862
|
2,878
|
1,270
|
443
|
Capex / Sales
|
19.51%
|
16.47%
|
31.9%
|
23.3%
|
10%
|
3.3%
|
Announcement Date
|
03/07/18
|
29/06/19
|
04/08/20
|
02/07/21
|
12/07/22
|
30/08/23
|
|
1st Jan change
|
Capi.
|
---|
| +36.51% | 472M | | +32.36% | 698B | | +26.51% | 568B | | -4.40% | 358B | | +19.46% | 328B | | +3.50% | 283B | | +16.34% | 238B | | +6.68% | 203B | | -9.08% | 198B | | +8.62% | 165B |
Other Pharmaceuticals
|